While significant advances have been made overall in the treatment of multiple myeloma, the management of transplant-ineligible patients remains challenging. Patients with multiple myeloma are not cured with conventional therapy. Treatment does, however, alleviate symptoms, improve quality of life, and prolong survival. The current standard of care for multiple myeloma patients includes an anti-CD38 monoclonal antibody in either first- or second-line treatment of myeloma. CANCER BUZZ spoke to Cindy Varga, MD, Hematologist at Atrium Health’s Levine Cancer Institute in Charlotte, NC. Listen as Dr. Varga discusses the positives and negatives with subcutaneous versus intravenous drugs in treating patients with multiple myeloma.
“There are benefits to the patient (for subcutaneous administration), it is very fast, as quick as 5-minutes. So. there is convenience there and less side effects.”
“Having patients be able to access these amazing drugs (both IV and subcutaneous) in their local infusion center, definitely helps with their up-front treatment plan. These patients are going into remissions, feeling better, and their quality of life is better on these drugs because they are so effective…”
- Cindy Varga, MD, Hematologist at Atrium Health’s Levine Cancer Institute
Cindy Varga, MD
Levine Cancer Institute at Atrium Health
This project is sponsored by Johnson & Johnson
ACCC is collaborating with The Leukemia & Lymphoma Society on this project.